✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Samatasvir is an investigational drug.
There have been 5 clinical trials for Samatasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Janssen Research & Development, LLC, and [disabled in preview].
There are twenty-five US patents protecting this investigational drug and three hundred and twelve international patents.
Recent Clinical Trials for Samatasvir
|Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)||Merck Sharp & Dohme Corp.||Phase 1|
|Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)||Janssen Research & Development, LLC||Phase 2|
|Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)||Merck Sharp & Dohme Corp.||Phase 2|
Top disease conditions for Samatasvir
Top clinical trial sponsors for Samatasvir
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Samatasvir||See Plans and Pricing||1',4'-thio nucleosides for the treatment of HCV||IDENIX PHARMACEUTICALS LLC (Cambridge, MA)||See Plans and Pricing|
|Samatasvir||See Plans and Pricing||Viral prophylaxis treatment methods and pre-exposure prophylaxis kits||ELIAN LLC (Monrovia, CA)||See Plans and Pricing|
|Samatasvir||See Plans and Pricing||Nucleotide and nucleoside therapeutic compositions and uses related thereto||Emory University (Atlanta, GA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Samatasvir||European Patent Office||EP3004130||2033-06-05||See Plans and Pricing|
|Samatasvir||World Intellectual Property Organization (WIPO)||WO2014197578||2033-06-05||See Plans and Pricing|
|Samatasvir||Australia||AU2015287994||2034-07-07||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|